
    
      This is a double-blind, randomized, placebo-controlled, multi-center study using the oral
      ORMD-0801 insulin formulation in patients with NASH and confirmed type 2 DM. The study will
      consist of a Screening Phase, Placebo Run-in Phase, Treatment Phase and an End-of-Study
      Phase. Approximately 36 subjects will be randomized in a 2:1 ratio to receive either 8 mg
      ORMD-0801, 1 capsule twice a day (once in the morning approximately 30 to 45 minutes prior to
      breakfast and no later than 10 AM, and once at night between 8 PM to Midnight and no sooner
      than 1 hour after dinner) or matching placebo.
    
  